Who We Are
4Living Biotech (4LB) is a clinical-stage, asset-centric company, established in mid-2020 as a Single Product Vehicle (SPV) of 4P-Pharma.
4Living Biotech develops first-in-class drug to treat Acute Respiratory Distress Syndrome (ARDS).
Breathing Hope For ARDS Patients
About Us
Our Mission
The company is dedicated to the clinical development of 4P021, a potential first-in-class treatment to improve both morbidity and mortality in ARDS.
By specifically targeting key markers of ARDS severity, 4P021 offers a tailored therapeutic approach. Its clinically demonstrated ability to stimulate the immune system further strengthens its potential as an effective long-term solution.
Tailored Therapeutic Approach
- December 2023
- Orphan Drug Designation
Scientific Foundations
-
Background
ARDS is an orphan designation and still a severe, life-threatening condition. Due to its highly heterogenous nature and the absence of specificbiomarkers, predicting ARDS progression and treatment responses remains challenging, hindering the advancement of personalized care.
-
Biomarkers for ARDS
Our team aims to identify early biomarkers to predict ARDS progression and identify treatment responders to CXCR4 antagonists. To accomplish this, we are developing a rapid test for precise patient stratification and optimized treatment decisions.
-
Our Scientific Innovation
Our innovation is based on a patient-centered approach, aiming to target specific mechanisms of action and stratify patients. The goal is to identify a biomarker capable of predicting the progression of Acute Respiratory Distress Syndrome (ARDS) throughout the patient’s journey. This identification will enable us to recognize patients who respond to the treatment and develop a rapid test for precise stratification and treatment optimization. These treatments will be defined in our Phase 2 clinical trial, 4P021.
Therapeutic Approach
4P021, potential ARDS game-changer
Our Approach
We have created an approach to identify early markers for predicting the severity of ARDS.
This initial phase, conducted under the Chopin clinical study, aims to select reliable indicators to forecast the disease progression in patients.
Preclinical and Clinical Studies
Concurrently, a preclinical study by 4P-Pharma focuses on identifying responder and non-responder patients.
By correlating the results of these preclinical and clinical studies, we can determine which markers are most relevant for assessing patient response.
Companion Kit Development
We are also developing a companion kit that incorporates the identified markers.
This kit will enable rapid identification, within 5 to 10 minutes, of patients of interest using either blood samples or tracheal aspirations.
Phase 2 Clinical Trial
All these efforts aim to conduct a Phase 2 clinical trial.
The companion kit will help select patients for inclusion, optimizing the trial design and ensuring that the most relevant patients are enrolled.
Our Drug Candidates
Our approach is multifaceted to address diverse healthcare challenges.
Respiratory & infectious diseases
Preclinical
CHOPIN trial
Phase I
Phase II
Phase III
-
4P-021
Summary:
4P021 is a CXCR4 antagonist for a curative treatment of acute respiratory distress syndrom (ARDS) and pulmonary complications. 4P021 was developed in collaboration with Prof.
Patrick Berger‘s team from CHU de Bordeaux, Bordeaux University and INSERM, SATT Aquitaine, and Prof. François Trottein’s team from Institut Pasteur de Lille. Today, 4P021 is owned by 4P-Pharma’s SPV – 4Living Biotech.
Epidemiology:
IA wide variety of aetiologies can lead to ARDS. Pneumonia, extrapulmonary sepsis, aspiration of gastric contents, noncardiogenic shock, transfusion, and severe trauma. Despite some improvements in ARDS supportive care, this syndrome still induces a high mortality rate. Indeed, the overall mortality rate is 43%.
-
CHOPIN trial
Summary:
4P021 is a CXCR4 antagonist for a curative treatment of acute respiratory distress syndrom (ARDS) and pulmonary complications. 4P021 was developed in collaboration with Prof.
Patrick Berger‘s team from CHU de Bordeaux, Bordeaux University and INSERM, SATT Aquitaine, and Prof. François Trottein’s team from Institut Pasteur de Lille. Today, 4P021 is owned by 4P-Pharma’s SPV – 4Living Biotech.
Partners
